Innate Pharma (IPHA) Other Operating Expenses (2021 - 2025)

Innate Pharma's (IPHA) quarterly Other Operating Expenses came in at $1164.0 in Q4 2025, up 15623527583500.0% on a QoQ basis from -$0.0 in Q2 2025.

Innate Pharma (IPHA) Other Operating Expenses (2021 - 2025) Analysis & Trends

Innate Pharma (IPHA) has 5 years of Other Operating Expenses data on file, last reported at $1164.0 in Q4 2025.

Quarterly Other Operating Expenses changed N/A year-over-year to $1164.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2240.9 (up 108.09% YoY) and the FY2025 annual result came in at -$1164.0, changed N/A from the prior year.
Other Operating Expenses advanced to $1164.0 in Q4 2025, from -$0.0 in the prior quarter.
In the past five years, Other Operating Expenses ranged from a high of $41.8 million in Q4 2022 to a low of -$0.0 in Q2 2021.
A 5-year average of $7.0 million and a median of $538.44 in 2023 frame the typical range for Other Operating Expenses.
Annual changes were most pronounced in 2024 — Other Operating Expenses surged 14453740380100.0% — and 2025, when it tumbled 100.0%.
Tracing IPHA's Other Operating Expenses over 5 years: stood at -$0.0 in 2021, then surged by 5.614346618093811e+17% to $41.8 million in 2022, then tumbled by 100.0% to $0.0 in 2023, then surged by 14453740380100.0% to $1076.9 in 2024, then climbed by 8.09% to $1164.0 in 2025.
The last three Other Operating Expenses figures came in at $1164.0 (Q4 2025), -$0.0 (Q2 2025), and $1076.9 (Q2 2024), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Innate Pharma	187.25 Mn	187.25 Mn	-

Download Data